Solid Biosciences SLDB
NASDAQ SLDB
$7.74 +0.57 (+8.02%)
As of: Nov 11, 2026 · 11:06 AM EST

Solid Biosciences (SLDB) Non-Current Deferred Revenue (2020 - 2021)

Updated

Solid Biosciences' Non-Current Deffered Revenue came in at $2.26 million for Q3 2021, down 47.5% from the prior quarter.

Analysis

Solid Biosciences (SLDB) Non-Current Deferred Revenue (2020 - 2021) Analysis & Trends

At the end of FY2020, Solid Biosciences' Non-Current Deffered Revenue was $10.36 million.

  • Business Quant data shows SLDB's Non-Current Deffered Revenue at $4.31 million (Q2 2021), $7 million (Q1 2021) and $10.36 million (Q4 2020) in the three quarters before Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Solid Biosciences 1.08 Bn -212.24 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 2.26 Mn
Jun 30, 2021 4.31 Mn
Mar 31, 2021 7.00 Mn
Dec 31, 2020 10.36 Mn
API Access

Solid Biosciences Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=SLDB&period=max&api_key=YOUR_API_KEY